HUTCHMED DRC

HUTCHMED DRC

Yahoo Finance • 4 days ago

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

HUTCHMED (China) Limited — Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically signifi... Full story

Yahoo Finance • 20 days ago

3 British Healthcare Stocks To Own In October 2026

Rising energy costs and inflation worries are putting pressure on many sectors, yet healthcare spending in the UK tends to be more resilient when wallets tighten. That gives high quality British healthcare stocks with solid balance sheets... Full story

Yahoo Finance • 23 days ago

How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo

AstraZeneca, in collaboration with HUTCHMED, has submitted a New Drug Application to the US FDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in previously treated EGFR-mutated NSCLC patients with MET overexpression or amplifica... Full story

Yahoo Finance • last month

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED (China) Limited — Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy — — Application supported b... Full story

Yahoo Finance • last month

Chinese biopharma stocks rally as U.S. signals openness to drug licensing

[Stock market data with uptrend vector] sitox * Shares in Chinese biopharma stocks rose on Monday, with Innovent Biologics (IVBIY [https://seekingalpha.com/symbol/IVBIY]) rising 7% and Akeso (AKESF) up 8% after a report that the U.S. ma... Full story

Yahoo Finance • 2 months ago

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Key Points Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED signed a deal with GSK worth up to approximately $1.3 billion for ex-China rights to HMPL-A830, including a $110 million upfron... Full story

Yahoo Finance • 2 months ago

HUTCHMED jumps 15% after licensing cancer therapy to GSK for up to $1.295B

* HUTCHMED (HCM [https://seekingalpha.com/symbol/HCM]) said [https://seekingalpha.com/pr/20639242-hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer] it signed an exclusive licensing deal with GSK (GS... Full story

Yahoo Finance • 2 months ago

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

HUTCHMED (China) Limited — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in... Full story

Yahoo Finance • 3 months ago

HUTCHMED H1 Earnings Call Highlights

Key Points Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED remained profitable in H1 2026, reporting $162 million in oncology revenue, up 23% year over year, and $16 million in net incom... Full story

Yahoo Finance • 4 months ago

HUTCHMED to Announce 2026 Half-Year Financial Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, Jul... Full story

Yahoo Finance • 4 months ago

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harborin... Full story

Yahoo Finance • 5 months ago

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently devoid of approved... Full story

Yahoo Finance • 5 months ago

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Wei... Full story

Yahoo Finance • 6 months ago

Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma

(RTTNews) - HUTCHMED (HCM) and Innovent Biologics, Inc (HKEX:1801) said the China National Medical Products Administration (NMPA) has approved the combination of ELUNATE (fruquintinib) and TYVYT (sintilimab injection) for patients with loc... Full story

Yahoo Finance • 6 months ago

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801) today jointly announce that the New Drug... Full story

Yahoo Finance • 6 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, April 28, 2026 featuring live webcast presentations from international co... Full story

Yahoo Finance • 7 months ago

Agriculture, Construction, & Mining Machinery Industry Research Report 2026: Market to Reach $1.64 Trillion by 2032 - How Electrification and Telematics are Transforming Design

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Agriculture, Construction, & Mining Machinery Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Agriculture, Construction, & Mining Machi... Full story

Yahoo Finance • 7 months ago

Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stor... Full story

Yahoo Finance • 7 months ago

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-7... Full story

Yahoo Finance • 8 months ago

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology... Full story